When expanding the analysis to include all EOCRC patients regardless of tumor subsites, the difference remained: 90.2% of H/L patients harbored TP53 pathway alterations compared to 85.05% of NHW patients (OR = 1.62, 95% CI: 0.926–2.825; p = 0.114) (Figure S1). Here, TP53 is linked to neoplasm.